Zoledronate Following Denosumab Discontinuation: Partial Reassurance but No Confidence
J Bone Miner Res
.
2020 Jul;35(7):1205-1206.
doi: 10.1002/jbmr.4022.
Epub 2020 Apr 21.
Author
Serge Ferrari
1
Affiliation
1
Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland.
PMID:
32315077
DOI:
10.1002/jbmr.4022
No abstract available
Publication types
Editorial
Comment
MeSH terms
Bone Density
Denosumab*
Diphosphonates / adverse effects
Female
Humans
Postmenopause*
Zoledronic Acid
Substances
Diphosphonates
Denosumab
Zoledronic Acid